Ipsilateral Recurrence, Recurrent Breast Carcinoma
Conditions
Keywords
single-dose preoperative radiotherapy, pathologic response, radiologic response, cosmetic outcome, partial breast irradiation
Brief summary
Over the past decades, interest in second breast-conserving therapy (BCT) has increased due to, among others, advancements in radiotherapy techniques. Preoperative partial breast irradiation (PBI) is an experimental treatment for patients with low-risk primary breast cancer. This approach can downstage the tumor, and may possibly reduce toxicity and improve cosmetic outcomes compared to postoperative radiotherapy. This study aims to evaluate the feasibility of single-dose preoperative PBI and second breast-conserving surgery (BCS) for patients with an ipsilateral recurrent breast event (IRBE) after previous BCT. The REPEAT trial is a multicenter, prospective, single-arm trial investigating ablative single-dose preoperative PBI in patients with an IRBE. Eligible patients are ≥ 50 years, have a unifocal non-lobular invasive breast cancer ≤ 2 cm, Bloom-Richardson grade 1 or 2, estrogen receptor-positive, HER2-negative and clinically negative axillary lymph nodes. The study plans to enroll 25 patients. Radiotherapy planning will involve the use of CT and MRI in the treatment position. Single-dose PBI of 20 Gy to the tumor and 15 Gy to the surrounding 2 cm of breast tissue will be delivered using a conventional or MR-guided linear accelerator. Tumor response will be monitored preoperatively using MRI and liquid biopsies to identify biomarkers for evaluating radiosensitivity. BCS will be performed 3 weeks post-PBI. The primary endpoint is the incidence of grade 2 or higher treatment-associated acute toxicity within 90 days. Secondary endpoints include the evaluation of acute (grade 1) and late toxicity, radiologic and pathologic response, mastectomy rate, patient-reported outcomes, cosmetic outcome, local, regional and distant recurrence rates, survival outcome, and biomarkers in liquid biopsies and tumor tissue. Patients will be followed up to 5 years after PBI. This trial will evaluate the feasibility of single-dose preoperative PBI and BCS for patients with IRBE. This treatment approach is expected to minimize the irradiated volume, reduce toxicity, and improve cosmetic outcomes compared to postoperative PBI after second BCS. Identifying biomarkers for radiosensitivity will help in selection patients and tailoring treatment.
Interventions
RADIATIONablative single-dose PBI
ablative single-dose PBI followed by BCS after three weeks At baseline (prior to RT) and prior to BCS, toxicity, PROMS and cosmetic outcome will be assessed. Additionally, a preoperative MRI will be performed three weeks following RT to evaluate the acute tumor response.
Sponsors
Amsterdam UMC, location VUmc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* WHO performance scale ≤ 2 * Females at least 50 years of age with an ipsilateral invasive breast cancer event or DCIS (i.e. recurrence, second primary) after previous breast conserving surgery and radiotherapy (for invasive breast cancer/carcinoma in situ) * Tumor characteristics: - - Tumor size ≤ 2 cm, unifocal on MRI On tumor biopsy: * Bloom-Richardson grade 1 or 2, * non-lobular invasive histological type carcinoma, * accompanying (non-extensive) DCIS is accepted within the tumor size of 2 cm on mammography and/or tumor biopsy, including no non-mass enhancement on MRI, * ER-positive and HER2-negative tumor, * No lymphovascular invasion. * Clinical node negative on PET-CT, ultrasound and MRI * No distant metastases * Repeat breast-conserving surgery is feasible, if no or mild late toxicity (no grade 2 or higher) from previous breast-conserving therapy * Adequate communication and understanding skills of the Dutch language * Written informed consent
Exclusion criteria
* Ipsilateral invasive breast cancer recurrence less than 2 years after first breast conserving therapy for breast cancer or ductal carcinoma in situ * Legal incapacity * Known breast cancer mutation gene carrier * Previous ipsilateral mastectomy * Collagen synthesis disease (e.g. Osteogeneis imperfecta, Ehlers-Danlos syndrome, systemic lupus erythematosus) * Invasive lobular carcinoma * MRI absolute contraindications as defined by the Department of Radiology * Indication for treatment with neoadjuvant chemotherapy * Non-feasible dosimetric RT plan * Breast implants
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acute toxicity | 90 days | The incidence of grade 2 or higher treatment-associated acute toxicity within 90 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Toxicity | 3,6,12 weeks and 1,2,3,4,5 years | Assessment of treatment-induced toxicity |
| response | 3,6,12 weeks and 1,2,3,4,5 years | Assessment of radiologic and pathologic response, mastectomy rate |
| PROMS | 3,6,12 weeks and 1,2,3,4,5 years | Assessment of PROMs |
| cosmetic results | 3,6,12 weeks and 1,2,3,4,5 years | Assessment of cosmetic results |
| oncological outcomes | 1,2,3,4,5 years | Assessment of oncological outcomes |
| immune response | 3,6,12 weeks and 1,2,3,4,5 years | Assessment of RT-associated immune response and biomarkers in blood and tumor tissue |
| patient comfort during RT treatment delivery | during RT treatment | Assessment of patient comfort during RT treatment delivery |
Countries
Netherlands
Contacts
CONTACTJanneke F van Roij, MD
PRINCIPAL_INVESTIGATORDesiree HJG van den Bongard, MD PhD
Amsterdam UMC
Outcome results
None listed